Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 5,239,200 | 4,580,100 | 9,158,000 | 10,369,100 | 11,110,200 |
| Marketable Securities | 1,285,300 | 1,215,400 | 1,013,300 | 849,200 | 818,000 |
| Receivables | 1,750,600 | 1,656,100 | 1,793,200 | 1,563,400 | 1,538,700 |
| Inventories | 1,079,800 | 914,600 | 813,100 | 738,800 | 688,700 |
| TOTAL | $9,804,100 | $8,941,600 | $13,288,700 | $14,144,200 | $14,695,800 |
| Non-Current Assets | |||||
| PPE Net | 1,117,800 | 1,200,900 | 1,172,800 | 1,159,300 | 1,124,000 |
| Investments And Advances | 4,703,500 | 4,393,100 | 4,381,400 | 2,497,800 | 1,700,000 |
| Intangibles | 1,919,600 | 1,925,500 | 1,922,900 | 1,927,900 | 1,691,600 |
| Other Non-Current Assets | 4,695,200 | 3,671,000 | 3,151,600 | 3,001,000 | 2,514,800 |
| TOTAL | $12,436,100 | $11,190,500 | $10,628,700 | $8,586,000 | $7,030,400 |
| Total Assets | $22,240,200 | $20,132,100 | $23,917,400 | $22,730,200 | $21,726,200 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 395,800 | 327,900 | 351,400 | 364,900 | 375,900 |
| Accrued Expenses | 3,219,700 | 2,940,000 | 2,795,900 | 2,655,300 | 2,907,300 |
| Other current liabilities | 357,600 | 279,300 | 648,600 | 527,200 | 316,200 |
| TOTAL | $3,973,100 | $3,547,200 | $3,795,900 | $3,547,400 | $3,599,400 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 2,522,200 | 1,463,600 | 1,213,400 | 1,226,300 | 1,223,700 |
| TOTAL | $2,636,200 | $1,810,200 | $1,574,900 | $1,602,400 | $1,614,000 |
| Total Liabilities | $6,609,300 | $5,357,400 | $5,370,800 | $5,149,800 | $5,213,400 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 257,529 | 258,102 | 258,053 | 258,308 | 257,683 |
| Common Shares | 2,600 | 2,600 | 2,600 | 2,600 | 2,600 |
| Retained earnings | 8,693,800 | 7,648,400 | 11,242,000 | 10,142,400 | 9,173,600 |
| Other shareholders' equity | 28,800 | 22,500 | 17,300 | -14,300 | -3,000 |
| TOTAL | $15,630,900 | $14,774,700 | $18,546,600 | $17,580,400 | $16,512,800 |
| Total Liabilities And Equity | $22,240,200 | $20,132,100 | $23,917,400 | $22,730,200 | $21,726,200 |